Navigation Links
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

Clinical Development. In addition, Judith A. Fox, Ph.D., has been promoted to Vice President, Product and Preclinical Development and Glenn C. Michelson, M.D., has been promoted to Vice President, Clinical Strategy.

To date, voreloxin has demonstrated objective responses in both solid and hematologic tumors and has been consistently well tolerated in multiple clinical trials. Sunesis is currently conducting Phase 2 clinical trials of voreloxin as a single agent for the treatment of platinum-resistant ovarian cancer and previously untreated acute myeloid leukemia (AML), as well as a Phase 1b clinical trial of voreloxin in combination with cytarabine in relapsed/refractory AML. Data recently reported at the 44th ASCO Annual Meeting in the Phase 2 ovarian cancer trial demonstrated that 48 percent of platinum-resistant ovarian cancer patients treated at a dose of 48 mg/m2 once every 21 days achieved disease control, defined as stable disease for 90 days or more or a complete or partial response. Preliminary median progression- free survival in this group of patients was 13 weeks at this dose; twenty- three patients at this dose remained on study as of May 12, 2008. Later this month, at the European Hematology Association Congress, Sunesis will report updated data on voreloxin's activity alone, and interim data on voreloxin's activity in combination with cytarabine for the treatment of AML.

Sunesis continues ongoing trials in its earlier-stage clinical programs, including the Phase 1 dose-escalation study of its cyclin-dependent kinase inhibitor, SNS-032, and its pan-Aurora kinase inhibitor, SNS-314, and expects to report data from these clinical trials this year. The company plans to seek a development partner to support advanced clinical trials of SNS-314. Future development of SNS-032 will depend on achieving positive results from the ongoing trial.

With the closing of its internal discovery research activities, Sunesis will also explore opportun
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
4. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
8. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Mass. , Aug. 27, 2014 North American ... a prestigious R&D 100 Award for the new OSRAM ITOS ... and LED-based white light module for microscopy, endoscopy and surgical ... lamps with significantly higher efficacy and lamp life. ... as one of the most innovative new technologies of the ...
(Date:8/27/2014)... STATESVILLE, N.C. , Aug. 27, 2014 ... today its Board of Directors increased its quarterly cash ... from eleven cents per outstanding share, beginning with the ... record at the close of business on September 8, ... Founded in 1906, Kewaunee Scientific Corporation is ...
(Date:8/27/2014)... , Aug. 27, 2014  Columbia Laboratories, Inc. (Nasdaq: ... provider of pharmaceutical development, clinical trial manufacturing, and advanced ... announced that it will participate at the upcoming Rodman ... to be held in New York ... 11:15am on September 9, 2014 at the New York ...
Breaking Medicine Technology:OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3
(Date:8/27/2014)... August 27, 2014 Skirt Sports , ... its partnership with pioneer runner, Kathrine Switzer, most noted for ... The collaboration creates a line of women’s running clothes that ... message of Kathrine’s 261 Fearless Movement. , “It ... icon,” said Nicole DeBoom. “Kathrine is the original Skirt ...
(Date:8/27/2014)... 2014 New Jersey’s own Morgan Hoffmann ... County Club during The Barclays – and thanks to ... the tournament’s four rounds, stepped his way into raising ... Blue Shield of New Jersey (Horizon BCBNSNJ) Walking Challenge. ... native playing before family and friends at the Paramus ...
(Date:8/27/2014)... Dennis Thompson HealthDay ... Someone who has been mugged in a dark alley will ... with a fear of being attacked. But neuroscientists working ... how memories are linked with positive and negative emotions. And ... emotions attached to a memory. In essence, they made ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Ticket Down ... Chile tickets at Levi’s Stadium in Santa Clara. ... Santa Clara, California just opened in July and will host ... Mexico takes on Chile. These are two of the best ... 2014 World Cup and will look to continue their successes ...
(Date:8/27/2014)... lipids are known to play a key role in ... like atherosclerosis. A new study at UCLA demonstrates that ... lung disease that narrows the small blood vessels in ... showed that a peptide mimicking part of the main ... may help reduce the production of oxidized lipids in ...
Breaking Medicine News(10 mins):Health News:Skirt Sports Launches Clothing Line with Legendary Runner Kathrine Switzer 2Health News:Morgan Hoffmann, PGA TOUR Pro & Wyckoff Native, golfs and walks his way to top 10 finish at The Barclays while raising additional $7,500 for charity 2Health News:Scientists 'Rewrite' Bad Memories in Mice 2Health News:Scientists 'Rewrite' Bad Memories in Mice 3Health News:Mexico vs. Chile Tickets at Levi’s Stadium: Ticket Down Cuts Ticket Prices for Inaugural Soccer Match between Chile and Mexico in Santa Clara 2Health News:Mexico vs. Chile Tickets at Levi’s Stadium: Ticket Down Cuts Ticket Prices for Inaugural Soccer Match between Chile and Mexico in Santa Clara 3Health News:Protein in 'good cholesterol' may be a key to treating pulmonary hypertension 2
... Md., Jan. 7 Hanger Orthopedic Group, Inc. (NYSE: ... its results of operations for the year ended December 31, ... a press release announcing the results for the year ended ... close of the market. The conference call is scheduled to ...
... identified mutations in a gene that predict a high ... (ALL). Although the researchers caution that further research is ... IKZF1 or IKAROS, lead to leukemia relapse, the findings ... tests to assess the risk of treatment failure. ...
... to Provide Support and Convenience CARLSBAD, Calif., Jan. ... of a new on-line service for physicians and ... and products. The new Web site, www.skinmedica.com ... physicians while offering the convenience of on-line information ...
... Seabrook House, an internationally recognized inpatient treatment center, is ... programs in 2009. The following is just a few ... that recovery from addiction is possible and that treatment works. ... family who needs it and to educate the public at ...
... (NYSE: MED ), a leading portion-controlled weight-loss program, ... Baltimore SmartCEO magazine. Medifast is a 2007 and ... the 50 fastest growing companies in the Greater Baltimore area ... 16, 2008 that The Company expects revenues in excess of ...
... Colo., Jan. 7 Zuma,s Rescue Ranch received its ... years of being self funded, Zuma,s Rescue Ranch can ... had a very busy 2008, along with formally becoming ... Health Institute on getting Medicaid to cover Equine Assisted ...
Cached Medicine News:Health News:Hanger Orthopedic Group, Inc. Announces 2008 Year-End Earnings Release Conference Call 2Health News:Gene abnormality found to predict childhood leukemia relapse 2Health News:Gene abnormality found to predict childhood leukemia relapse 3Health News:Gene abnormality found to predict childhood leukemia relapse 4Health News:SkinMedica Launches On-Line Service for Physician Partners 2Health News:Seabrook House Embraces the New Year with New Programs 2Health News:Seabrook House Embraces the New Year with New Programs 3Health News:Medifast Named Baltimore SmartCEO Future 50 Company for Second Time 2
Calcar replacement stems provide options for revision and trochanteric fractures. Revision hip surgery and trauma often require prosthetic designs that replace proximal medial calcar bone loss....
...
...
... for the restoration of shoulder joint ... surgery. Backed by the clinical expertise ... the Bigliani/Flatow Shoulder System is designed ... balance, and stability with a multitude ...
Medicine Products: